Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 19/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059628 | 1.00 | CACNA1G (0.35) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL1064055 | 0.93 | GCK (0.38) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL1062440 | 0.93 | GCK (0.38) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL1062438 | 0.93 | GCK (0.38) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL4299352 | 0.92 | GCK (0.37) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL1063964 | 0.92 | GCK (0.37) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL4292902 | 0.90 | GCK (0.37) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL4294245 | 0.90 | GCK (0.37) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL4296975 | 0.88 | GCK (0.44) | CACNA1GCACNA1HCACNA1IGCK | |
| SCHEMBL1062107 | 0.88 | GCK (0.44) | CACNA1GCACNA1HCACNA1IGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | CACNA1G 4277/4885CACNA1H 4512/4885CACNA1I 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.